Cytokinetics Starts Trial For CK-586 In HFpEF

(RTTNews) - Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF trial, a Phase 2 clinical study to evaluate CK-586 in patients with symptomatic heart failure with preserved ejection fraction or HFpEF.

CK-586 is a cardiac myosin inhibitor in development for the treatment of a subgroup of HFpEF patients who exhibit hypercontractility and ventricular hypertrophy.

The AMBER-HFpEF trial is a randomized, double-blind, placebo-controlled, multi-center study designed to assess the safety, tolerability, and efficacy of CK-586.

This trial builds on promising data from previous studies in related conditions such as non-obstructive hypertrophic cardiomyopathy or nHCM.

The trial aims to provide further insights into CK-586's potential to improve heart function and symptoms in patients with HFpEF, a condition that significantly impacts quality of life and has a poor prognosis despite advances in heart failure treatments.

Cytokinetics plans to enroll approximately 60 patients across three escalating doses to evaluate CK-586's effects on key cardiovascular markers.

The trial marks a critical step in the company's goal to provide targeted, effective therapies for heart failure patients with preserved ejection fraction.

Currently, CYTK is trading at $45.70 down by 0.09%.